Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 30, 2001

View Archived Issues

Millennium granted license to novel target for colorectal cancer

Angiotech to expand phase II study of Paxceed for secondary progressive multiple sclerosis

OSI acquires Gilead's oncology assets

Boehringer Ingelheim and ImmunoGen to develop new TAP product

Phase I trial initiated for nasal administration of interferon beta

Halofuginone enters phase I/II trial for advanced-stage cancer

Lupus kidney disease drug candidate LJP-394 designated an orphan drug in Europe

Squalamine enters phase IIb non-small cell lung cancer trial

Phase II trial of Endostatin for the treatment of neuroendocrine tumors commences

Rec-15/3079 exerts beneficial effects on bladder function without unwanted CNS side effects

Novel peptide antibiotics isolated for the first time from mast cells

Human umbilical cord blood cells in the treatment of stroke

First launch for Lilly's Xigris within days of approval

Novel glutamate AMPA receptor antagonist may have potential in ALS

Morphinan derivatives with high affinity for kappa and mu opioid receptors for Rx of cocaine abuse

Rigel receives milestone from Pfizer for respiratory drug target validation

Regeneron's VEGF Trap enters phase I trial

New class of antifungal agents targeting N-myristoyltransferase designed at Roche

New substituted adenine interferon inducers under study by Japan Energy and Sumitomo

Broad series of 5-HT receptor ligands designed by Pharmacia

Pfizer reveals potential new antiinflammatory/analgesic agents

Japanese patent covers Suntory's new nicotinic acetylcholine receptor agonists

Effective and safe anorectic agents emerge from R&D at Mitsui Chemicals

Novel hydrazide derivatives inhibit apoB-associated lipoprotein secretion

Cell death inhibitors under investigation by Sagami

J-124131: a new antitumor antibiotic identified at Banyu

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...